Share this page
Netherlands10/11/2023
IPIC 2023
Octapharma Symposium
Clinical cases: Uncovering atypical manifestations of PID
Friday, 10 November 2023
13:45 - 14:45 CET
Room: Rotterdam Hall
Classical immunodeficiencies are mainly characterized by infectious conditions. Although in the recent years manifestations related to allergy, inflammation, autoimmunity, lymphoproliferation, and malignancies have been described, it can be difficult to unravel the relationship between primary immunodeficiencies (PID), secondary immunodeficiencies (SID) and hematological malignancy or autoimmunity in the clinical setting.
During this session, the audience will actively participate in the discussion around interactive clinical cases showcasing atypical manifestations of PID with various clinical presentations.
Symposium programme
Programme | Speaker |
|---|---|
Welcome and introduction | Chair: Elie Haddad (Montreal, Canada) |
Case 1: Unmasking PID in a SID patient with haematological malignancy | Stephen Jolles (Cardiff, UK) |
Case 2: A surprising diagnosis | Elie Haddad (Montreal, Canada) |
Case 3: Could neuropsychiatric disorders PANS/PANDAS be associated with PID? | Michael Daines (Tucson, Arizona, USA) |
Closing Remarks | Elie Haddad (Montreal, Canada) |
This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program was developed for use outside the U.S., is intended for non-U.S. HCPs, and is to be used in accordance with local laws and regulations.
Meet the speakers
Chair: Elie Haddad
Sainte-Justine University Hospital, Montreal, Canada
Stephen Jolles
University Hospital of Wales, Cardiff, UK
Michael Daines
University of Arizona, Tucson, USA
To attend this symposium, register to the IPIC 2023 congress.
Visit event page on Science Hub
Are you unable to attend this event? Visit Science Hub to access the session recording.
Learn more about SID
Visit our information hub for healthcare professionals to learn more about secondary immunodeficiencies and hematological malignancies.